Tuesday December 12, 2017 13:19

Heathcare Press Release : 07 Dec 2017

Ryzodeg(R) Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Heathcare—07 Dec 17

In people with type 2 diabetes who fast during Ramadan, Ryzodeg(R) (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus

Tresiba(R) Reduces Hypoglycaemia Regardless of Blood Sugar Level Heathcare—07 Dec 17

People with either type 1 or type 2 diabetes treated with Tresiba(R) had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.[1] These new post-hoc